Chenjun Huang

Chenjun Huang

Auto-generated profile, based on publicly available information

Chenjun Huang

Department of Clinical Laboratory Medicine Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2021 in Liver International
Verified
Journal Article
Closed access
CHChenjun Huang
Chenjun Huang
MFMeng Fang
Meng Fang
XXXiao Xiao
Xiao Xiao
HWHong Wang
Hong Wang
ZGZhiyuan Gao
Zhiyuan Gao
CGChun-Fang Gao
Chun-Fang Gao

17 March 2021 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
CHChenjun Huang
Chenjun Huang
MFMeng Fang
Meng Fang
HFHuijuan Feng
Huijuan Feng
LLLijuan Liu
Lijuan Liu
YLYa Li
Ya Li
CGChunfang Gao
Chunfang Gao

8 December 2023 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
CHChenjun Huang
Chenjun Huang
XXXiao Xiao
Xiao Xiao
LZLin Zhou
Lin Zhou
FCFuxiang Chen
Fuxiang Chen
JWJianyi Wang
Jianyi Wang
CGChun-Fang Gao
Chun-Fang Gao
Background: Primary hepatocellular carcinoma (HCC) is one of the most prevalent world‐wide malignancies. Half of the newly developed HCC occurs in China. Optimizing the strategies for high‐risk surveillance and early diagnosis are pivotal for improving 5‐year survival. Constructing the scientific non‐invasive detection technologies feasible for medical and healthcare institutions is among the key routes for elevating the efficacies of HCC identification and follow‐up.Results: Based on the Chinese and international guidelines, expert consensus statements, literatures and evidence‐based clinical practice experiences, this consensus statement puts forward the clinical implications, application subjects, detection techniques and results interpretations of the triple‐biomarker (AFP, AFP‐L3%, DCP) based GALAD, GALAD like models for liver cancer.Conclusions: The compile of this consensus statement aims to address and push the reasonable application of the triple‐biomarker (AFP, AFP‐L3%, DCP) detections thus to maximize the clinical benefits and help improving the high risk surveillance, early diagnosis and prognosis of HCC.

11 February 2021 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
CHChenjun Huang
Chenjun Huang
XXXuewen Xu
Xuewen Xu
MWMengmeng Wang
Mengmeng Wang
XXXiao Xiao
Xiao Xiao
CCCheng Cheng
Cheng Cheng
CGChun-Fang Gao
Chun-Fang Gao

25 April 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
CHChenjun Huang
Chenjun Huang
MFMeng Fang
Meng Fang
XXXiao Xiao
Xiao Xiao
ZGZhiyuan Gao
Zhiyuan Gao
YWYing Wang
Ying Wang
CGChun-Fang Gao
Chun-Fang Gao
Objectives: Wilson disease (WD) is a rare autosomal recessive genetic disorder associated with various mutations in the ATP7B gene and leads to significant disability or death if untreated. Early diagnosis and proper therapy usually predict a good prognosis, especially in pre‐symptomatic WD. Genetic testing provides an accurate and effective diagnostic method for the early diagnosis of WD.Methods: We recruited 18 clinically diagnosed WD patients from 16 unrelated families and two independent individuals. The next‐generation sequencing of the ATP7B gene was performed. The 293T cell lines were divided into wild‐type (WT) ATP7B and mutated ATP7B groups. Cell proliferation was determined by Cell Counting Kit‐8 (CCK‐8) assay and apoptosis was detected by Annexin V/propidium iodide (PI) assays.Results: Pedigree analysis showed that compound heterozygous variants (17/18, 94.44%) were present in the majority of WD patients. A total of 33 ATP7B gene variants were identified, including three variants with uncertain significance (VUS) [two splice mutations (c.51+2T>G, c.1543+40G>A) and one frameshift mutation (c.3532_3535del)]. The CCK‐8 and apoptosis assays demonstrated that the VUS of ATP7B could significantly affect the transportation of copper.Conclusions: The study revealed genetic defects of 16 Chinese families and two independent individuals with WD, which enriched the mutation spectrum of the ATP7B gene worldwide and provided valuable information for studying the mutation types of ATP7B in the Chinese populations. Genetic testing in WD patients is necessary to shorten the time to initiate therapy, reduce damage to the liver and improve the prognosis.

23 November 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
XXXiao Xiao
Xiao Xiao
JZJun Zhou
Jun Zhou
MFMeng Fang
Meng Fang
JJJun Ji
Jun Ji
CHChenjun Huang
Chenjun Huang
CGChun-Fang Gao
Chun-Fang Gao
Objective: Biliary tract cancer (BTC) is a rare malignancy and lack of effective diagnostic and prognostic marker. Here, we aimed to investigate the clinical implication of TP53 mutation detection in BTC using droplet digital PCR (ddPCR).Methods: TP53 gene (loci p.R175H, p.R248Q, p.R248W, and p.R273H) mutation frequencies of 45 pairs of tumor tissues (TTs) and adjacent normal tissues (ANTTs) were analyzed, respectively, using ddPCR. Meanwhile, the same detections were conducted in plasma cell‐free DNA (cfNDA) of 156 subjects including BTC, disease control (DC), and healthy controls (HC). The logistic regression algorithm was established to identify BTC. The correlations between mutations and clinicopathological features as well as the effects of TP53 mutation frequency on BTC prognosis were assessed.Results: The higher mutation of p.R175H was found in TTs compared with ANTT (p = 0.006). The mutation at p.R273H in cfDNA was also higher in BTC when compared with DC and HC (p < 0.05). The logistic algorithms combining p.R273H mutation demonstrated the higher diagnostic efficacy trend than carbohydrate antigen 19–9 (CA19‐9), carcinoembryonic antigen (CEA), and alpha‐fetoprotein (AFP) in identifying BTC from DC (the area under the curves of the algorithm: 0.845, 95% CI:0.775–0.914). The median overall survival (OS) and progression‐free survival (PFS) were significantly shorter when the BTC patients harboring the p.R273H mutation (OS: p = 0.032; PFS: p = 0.046).Conclusion: This study revealed for the first time that the quantitative TP53 mutations using the ddPCR might serve as a potential genetic biomarker for BTC diagnosis and prognosis assessment.